Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd., founded in Taipei, Taiwan, in 2013, operates as a clinical-stage pharmaceutical firm. The company concentrates its efforts on the discovery, advancement, and marketing of medicinal products across the United States, China, and Europe. Its comprehensive pipeline includes two main categories: stabilized injectable formulations and novel chemical entities. The stabilized injectable portfolio features: FP-001, which has successfully completed Phase III clinical trials for treating advanced prostate cancer. FP-004, currently in preclinical development, targeting opioid use disorder. FP-011 and FP-014, designed as long-acting, sustained-release drug candidates for managing breast and prostate cancers. FP-016, aimed at addressing various neurological conditions. The new chemical entity pipeline comprises: FP-020, intended for the treatment of respiratory conditions such as sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema. FP-025, a selective matrix metalloproteinase-12 (MMP-12) inhibitor, which is currently in Phase II clinical trials for asthma, chronic obstructive pulmonary diseases (COPD), and acute respiratory distress syndrome (ARDS) in COVID-19 patients. FP-045, a selective aldehyde dehydrogenase (ALDH2) activator, that has finished its Phase I clinical study for Fanconi anemia. FP-040, another ALDH2 activator, being developed to treat central nervous system disorders.

CEO: Benjamin Chien - https://www.foreseepharma.com